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Arcobacters are potential pathogens related to diarrheic infections and, rarely, septicaemia. This study evaluated the prevalence of
arcobacters in stool samples of subjects with (n = 38) and without (n = 61) type 2 diabetes by using cultural and molecular
techniques. Three Arcobacter positive cultures were found, all among diabetic subjects, whereas molecular analysis showed a
carriage rate of 79% and 26.2% in subjects with and without type 2 diabetes (P<. 001), respectively. The multivariate analysis
showed that type 2 diabetes (β = 1.913; 95%CI: 2.378–19.285; P<. 0001) and age (β = 1.744; 95%CI: 2.077–15.766; P = .001)
were the only factors independently associated with arcobacters colonization in this population. Our study demonstrated a high
prevalence of arcobacters colonization in type 2 diabetic and older subjects. The clinical signiﬁcance and the potential health risk
associated with these emerging species remain to be determined.
1.Introduction
The genus Arcobacter currently includes ten species.
Pathogenic strains belonging to Arcobacter butzleri, Arcobac-
ter cryaerophilus, and Arcobacter skirrowii have been isolated
f r o mh u m a ns p e c i m e n s ,a sw e l la sf r o ma n i m a lf a e c e sa n d
food of animal origin [1–6]. Arcobacter nitroﬁgilis, Arcobacter
halophilus, as well as a number of recently published species
such as Arcobacter cibarius, Arcobacter marinus, Arcobacter
thereius and Arcobacter mytili, and the not yet established
species candidatus A. sulﬁdicus have been isolated from a
variety of sources, but not from humans yet [7–13].
Epidemiological data on arcobacters colonization in
humans are limited [1, 14, 15]; overall, the presence of these
potential pathogens seems to be generally low and seldom
associated with gastrointestinal disorders. Thus, A. butzleri,
A. cryaerophilus,a n dA. skirrowii have been mainly isolated
from stool specimens from patients with diarrhoea and in
some cases of septicemia [1–3, 16–20].
Most infections are believed to result from the ingestion
of contaminated food or water [21, 22], and the ubiquitous
environmental distribution of arcobacters may be related to
thehighoccurrenceofthesemicroorganismsinanimalfaecal
samples [4, 23].
Diabetic subjects seem to be particularly prone to
colonization by members of the Campylobacter family like
Helicobacter pylori [24, 25]. However, to date, there are no
data on carriage rate in this type of patients by Arcobacter,
another genus of this family.
In this study we investigated arcobacters carriage rates
and the clinical characteristics of a group of subjects with
and without type 2 diabetes and with no sign or symptom
for gastrointestinal disorders.
2.MaterialsandMethods
2.1. Subjects. A group of nonhospitalized subjects with (n =
38) and without (n = 61) type 2 diabetes, without any2 Journal of Biomedicine and Biotechnology
sign or symptom for gastrointestinal disorders, consecutively
attending the outpatient clinic for Metabolic disorders of
the Department of Internal Medicine of Messina University,
Italy, were recruited into this study. All study subjects gave
their informed consent and the study was approved by the
local ethical committee.
Lifestyle (socio-economical status, smoking) and clinical
data were collected from all participants through a standard-
ized questionnaire. Type 2 diabetes was diagnosed according
to ADA 1997 criteria [26], and all diabetic participants
were currently treated with diet, oral agents, insulin, or a
combination of them. Data on retinopathy, neuropathy, and
nephropathy,asdiagnosedaccordingtoADA2008guidelines
[27], as well as data on macrovascular disease, as deﬁned
as a composite end-point [28, 29] including documented
myocardial infarction, ischaemic heart disease, coronary
heart bypass, coronary angioplasty, cerebral thromboem-
bolism and peripheral amputations were also available for
diabetic subjects only.
2.2. Clinical and Laboratory Measurements. An accurate
physical examination was performed in each participant.
Weight, height, body mass index (BMI), waist circumference
and blood pressure, were also measured according to stan-
dard procedures.
Fasting blood samples were collected from all the par-
ticipants for measurements of the study parameters. Fasting
plasma glucose, lipid concentrations, as well as leukocyte
blood count and erythrocyte sedimentation rate (ESR)
were measured with standard laboratory methods. Glycated
haemoglobin (HbA1c) was measured using an automated
high-performance liquid chromatography analyzer (Diamat;
Bio-Rad Laboratories, Milan, Italy) in diabetic participants,
only; normal range values were 4–6%.
2.3. Specimen Collection. Stool samples from all partici-
pants were collected and readily sent to the laboratory for
subsequent analyses. On arrival in the laboratory, samples
were kept under cooled conditions until culture, which was
usually performed within 1 to 3 h of receipt.
2.4. Cultural Methods. For the isolation of Arcobacter spp.,
direct plating and enrichment procedures [30]w e r ea p p l i e d
to faecal samples emulsioned in approximately 1g/mL of
sterile saline.
2.5. Molecular Methods. PCR assay was performed to con-
ﬁrm presumptive isolates and was directly on DNA extracted
from stool samples, according to the manufacturer’s instruc-
t i o n s( Q I A a m pD N AS t o o lM i n iK i t( Q I A G E N ) ) .
Three pairs of primers targeting the 16S and 23S genes
were used in PCR assays for the detection and identiﬁcation
of arcobacters [31]. The CRY1-CRY2 primers ampliﬁed a
257-bp fragment from A. cryaerophilus, the ARCO-BUTZ
a 401-bp fragment from A. butzleri, and the ARCO-SKIR
a 641-bp fragment from A. skirrowii [31]. The primers
were synthesized by MWG-Biotech (Mannheim, Germany).
The ampliﬁcation was performed on a PCR Sprint Thermal
Cycler (Hybaid, UK), as previously described [32].
Brieﬂy, PCR conditions provided an initial denaturation
at 95◦C for 15min, followed by 35 cycles of denaturation
at 94◦C (1min), annealing at 50◦C (1min), extension at
72◦C (1min), and a ﬁnal extension at 72◦C for 10min. A
negative control lacking the DNA template was included
in each experiment. The Arcobacter strains used as positive
controls in the PCR tests included A. butzleri ATCC 49616T,
A. cryaerophilusATCC 43157, and A. skirrowii ATCC 51132T.
PCR products were then separated by electrophoresis on an
1.5% agarose gel, and DNA fragments were visualized by UV
illumination, after staining with ethidium bromide.
A random sample of positive PCR products from both
isolates (n = 3) and faecal DNA (n = 26) was conﬁrmed by
direct sequencingusing primers described byHouf et al.[31]
at the Genelab, ENEA, Rome (Italy).
2.6. Statistical Analysis. Statistical analysis was performed
using the SPSS program, version 11.0 for Windows (SPSS
Inc. Chicago, IL). Data are given as mean ± SD. We
used χ2 test to compare categorical measures and the
analysis of variance (ANOVA) for continuous measures.
Linear regression models were determined using a stepwise
selection procedure for all the factors, entering the contin-
uous variables with the use of appropriate transformations.
All statistical comparisons are two-tailed, and they were
considered signiﬁcant at the P<. 05 level.
3. Results
3.1. Clinical Characteristics of Study Population. Clinical
characteristics of the study population according to the
presence of type 2 diabetes are summarized in Table 1.
Overall, diabetic patients were older, with an acceptable
metabolic control despite the relatively long duration of
diabetes. Diabetic subjects also showed signiﬁcantly higher
values of BMI, waist circumference, fasting blood glucose,
andtriglyceridesandlowerconcentrationsoftotal,LDL-and
HDL-cholesterol as compared to nondiabetic subjects.
Infection laboratory indexes (ESR, leukocyte blood
count, and percentage of neutrophils) were within the
normal range, although with some diﬀerences between the
two groups (Table 1).
Also the percentage of smokers was higher in diabetic
versus controls (P = .05), whereas no other signiﬁcant
diﬀerences were noted between the two groups.
3.2. Prevalence of Arcobacter Colonization in the Study Popu-
lation. Data on the prevalence of Arcobacter in the examined
stool samples, as determined both by cultural and molecular
techniques, are shown in Table 1.
Only 3 of the 99 cultures were positive (3%), while
Arcobacter DNA was detected by PCR analysis in 46 (46.5%)
stool samples including the 3 samples positive by culture
that belonged to diabetic subjects. In particular, molecular
evidence of Arcobacter was noted in 30 (79%) subjects with
and 16 (26.2%) without type 2 diabetes (P<. 001).Journal of Biomedicine and Biotechnology 3
Table 1: Clinical characteristics and Arcobacter carriage rate in subjects with and without diabetes.
Type 2 diabetic subjects Non diabetic subjects P
n 38 61
Male sex n (%) 21 (55.3) 33 (54) —
Age (years) 63.1 ± 9.3∗ 54.3 ± 7.2 <.0001
BMI (kg/m2) 29.5 ± 4.3 27.1 ± 2.9 .001
Waist circumference (cm) 98.3 ± 9.2 91.6 ± 9.8 .001
Low instruction level n (%) 30 (78.9) 40 (65.6) —
Hypertension n (%) 20 (52.6) 25 (41.0) —
Current smokers n (%) 15 (39.5) 13 (21.3) .05
Diabetes duration (years) 10.9 ± 8.8 — —
Fasting blood glucose (mg/dL) 146.7 ± 49.3 90.8 ± 6.3 <.0001
HbA1c (%) 7.06 ± 1.34 — —
Total Cholesterol (mg/dL) 178.5 ± 37.9 199.4 ± 27.0 .001
LDL-Cholesterol (mg/dL) 104.1 ± 41.2 123.6 ± 28.0 .006
HDL-Cholesterol (mg/dL) 48.7 ± 9.4 54.4 ± 10.4 .008
Triglycerides (mg/dL) 132.6 ± 50.2 110.7 ± 50.6 .04
ESR (mm/hr) 10.3 ± 6.1 12.8 ± 6.2 .02
Leukocyte Blood Count/mm3 7317 ± 1552 6651 ± 1506 .04
Neutrophils (%) 58.6 ± 7.6 61.5 ± 5.6 .04
Positive cultures for Arcobacter n (%) 3 (7.9) 0 —
A. butzleri n (%) 1 (33.3) —
A. cryaerophilus n (%) 1 (33.3) —
A. butzleri and A. cryaerophilus n (%) 1 (33.3) —
Positive PCR for Arcobacter n (%) 30 (78.9) 16 (26.2) .001
A. butzleri n (%) 3 (10) 2 (12.25)
A. cryaerophilus n (%) 12 (40) 9 (56.25)
A. butzleri and A. cryaerophilus n (%) 15 (50) 5 (31.25)
∗Mean ± SD. Only signiﬁcant P-values are presented.
BMI: Body mass index.
HbA1c: Glycated haemoglobin, available for diabetic subjects only.
ESR: Erythrocyte Sedimentation Rate.
Of the 3 positive cultures, the PCR analysis revealed that
one was positive for A. butzleri, another for A. cryaerophilus,
and the third for both A. butzleri and A. cryaerophilus.
The sequences obtained from three of our Arcobac-
ter isolates (MTF1, MTF2, MTF3) conﬁrmed the PCR
data, showing a 100% sequence similarity with A. butzleri
(GenBank accession no.: AY621116) for MTF1 and a 98%
sequence similarity to A. cryaerophilus (GenBank accession
no.: X80383; AB081300) for both MTF2 and MTF3.
Of the 46 Arcobacter PCR positive samples, 21 (45.6%)
were positive for A. cryaerophilus, 20 (43.5%) for both A.
butzleri and A. cryaerophilus, and 5 (10.9%) for A. butzleri.
Comparing the sequences of 26 PCR products, randomly
selected among the 46 positive faecal DNA samples, with
previously published sequences in the GenBank database,
a very high degree of similarity of our sequences with A.
butzleri (accession no.: CP000361; AY621116; EU252504)
and A. cryaerophylus (accession no.: X80383; AB081300) was
found.
Neither A. skirrowii isolates nor A. skirrowii PCR prod-
ucts were found in our study. Figure 1 show a representative
example of PCR analysis of DNA extracted from faecal
samples.
The GenBank accession numbers for our nucleotide
sequences are as follows: GU116587, GU116588 and
GU116589 for the isolates MTF1, MTF2, MTF3, respectively,
and from GU108194 to GU108219 for the faecal DNA
sequences.
3.3. Clinical Diﬀerences in Diabetic and Nondiabetic Subjects,
According to Arcobacter Colonization. When clinical charac-
teristics of subjects with or without Arcobacter carriage were
compared in the diabetic and non diabetic groups separately
(Table 2), diabetic subjects with evidence of arcobacters were
signiﬁcantly older as compared to those without it (P<
.001), whereas no diﬀerences were noted in the other clinical
characteristics between the two groups (Table 2). Similarly,
no diﬀerences were noted in diabetes-related variables, such
as diabetes duration, current therapy with oral hypogly-
caemic agents and/or insulin, and the rate of micro- and/or
macrovascular complications between diabetic subjects with
or without Arcobacter colonization (data not shown).4 Journal of Biomedicine and Biotechnology
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Figure 1: Example of the PCR analysis of DNA extracted from the 3 reference strains and of ﬁve representative faecal samples using the
species speciﬁc primers. Lane M, 100-bp ladder; lanes 1–3 PCR products of the control strains: A. butzleri ATCC 49616T (401-bp), A.
cryaerophilus ATCC 43157 (257-bp), and A. skirrowii ATCC 51132T (641-bp), respectively. Lanes A, F, N, and B, G, O results obtained for
samples 1 and 2, respectively, showing only amplicons of the expected size for A. cryaerophilus; lanes C, H, P and D, I, Q, results obtained
from samples 3 and 4, respectively, showing only amplicons of the expected size for A. butzleri; lanes E, L, R, results obtained from sample
5 showing amplicons of the expected size for A. butzleri and A. cryaerophilus. None of the samples showed amplicons with the A. skirrowii-
speciﬁc primers; lanes 4 to 6, negative controls.
Table 2: Clinical characteristics in diabetic and nondiabetic subjects with or without evidence of Arcobacter colonization.









n 8 (21.1) 30 (78.9) 45 (73.8) 16 (26.2)
Male sex n (%) 3 (37.5) 18 (60.0) 24 (53.3) 9 (56.3)
Age (years) 54.1 ± 8.9∗ 65.8 ± 7.8† 54.0 ± 7.0 55.9 ± 8.2
BMI (kg/m2) 31.9 ± 6.4 28.8 ± 3.4 27.0 ± 2.8 27.7 ± 3.2
Waist circumference (cm) 99.4 ± 11.8 98.0 ± 8.7 90.2 ± 9.2 95.9 ± 10.6††
Low instruction level n (%) 5 (62.5) 25 (83.3) 30 (66.6) 10 (62.5)
Current smokers n (%) 3 (37.5) 12 (40.0) 10 (22.2) 3 (18.8)
Dyslipidemia n (%) 5 (62.5) 22 (73.3) 16 (35.5) 5(31.2)
Hypertension n (%) 3 (37.5) 17 (56.6) 14 (31.1) 11 (68.8)†
Fasting blood glucose (mg/dL) 136.5 ± 48.0 149.4 ± 50.1 90.0 ± 6.3 93.1 ± 5.9
HbA1c (%) 7.2 ± 1.2 7.1 ± 1.3 — —
Total Cholesterol (mg/dL) 165.2 ± 42.0 182.0 ± 36.6 198.8 ± 28.2 201.2 ± 23.5
LDL-Cholesterol (mg/dL) 91.7 ± 35.8 107.4 ± 42.5 124.5 ± 29.6 119.6 ± 22.1
HDL-Cholesterol (mg/dL) 46.6 ± 8.8 49.3 ± 9.7 54.1 ± 9.6 55.1 ± 12.6
Triglycerides (mg/dL) 141.7 ± 42.8 130.2 ± 52.3 111.0 ± 53.6 109.9 ± 42.7
∗Mean ± SD. Only signiﬁcant P-values are presented.
†P <. 001 versus subjects without Arcobacter colonization.
††P:.05 versus subjects without Arcobacter colonization.
BMI: Body mass index.
HbA1c: Glycated haemoglobin, available for diabetic subjects only.
In the non diabetic group (Table 2), carriers of arcobac-
ters had a signiﬁcantly higher waist circumference (P = .05)
and a higher rate of hypertension (P<. 001) as compared
to noncarriers. No other signiﬁcant diﬀerences in clinical
characteristics were noted between the two groups.
At multivariate analysis, performed in the whole pop-
ulation and including in the model all the variables that
showed signiﬁcant diﬀerences between subjects with and
without arcobacters (age, waist circumference, hypertension,
and diabetes), type 2 diabetes (β = 1.913;P<. 0001) and age
(β = 1.744;P = .001) were conﬁrmed as the only factors
independently associated with Arcobacter colonization in
this population, with a OR of 6.8 (95%CI: 2.378–19.285)
in diabetic versus non diabetic subjects, and an OR of 5.7
(95%CI: 2.077–15.766) in older versus younger subjects.
4. Discussion
Although data on healthy carriers are available worldwide
[14, 15, 33], our study is the ﬁrst investigation on the
prevalence of Arcobacter c a rri a g ei nd i a b e t i cs u b j e ct swi t h o u t
speciﬁc gastrointestinal symptoms in Italy.Journal of Biomedicine and Biotechnology 5
We found that type 2 diabetes and older age were
associated with an impressively high rate of Arcobacter
carriage. Overall, we found a high prevalence of Arcobacter
colonization with 46 positive cases by molecular analysis
and 3 positive cases by cultural methods, as evaluated by
both direct plating and enrichment procedures. Compared
to the cultural method, the PCR analysis identiﬁed 43 more
cases, namely 41.4% cases positive for A. cryaerophilus,
and 25.2% for A. butzleri;t h u sc o n ﬁ r m i n g ,a sp r e v i o u s l y
reported [32], the superiority of the molecular method over
the cultural one in arcobacters detection. However, several
other reasons may explain the very low detection rate for
Arcobacter with cultural methods in our study, including the
diﬀerences on isolation methods [17, 23, 34]. First of all,
it has been indicated that CAT agar supplemented media
that have been used in this study are not able to adequately
inhibit other faecal microorganisms [23, 35–37], that might
mask arcobacters, thus resulting in a lack of detection by
cultural methods. This was clearly improved in other studies
using the membrane ﬁltration method that produced a
reduction of the competitive microbiota [14, 23, 35–37].
Other authors found almost equal results between the m-
PCRdetectionmethods[31]fromtheenrichmentArcobacter
broth supplemented with CAT, by culturing the broth after
passive ﬁltration (0.45mm membrane ﬁlters) on blood agar
[23, 36].
Consistent with another study [15], we found that A.
cryaerophilus was the most frequently occurring species in all
the examined samples, whereas other authors have identiﬁed
A. butzleri as the dominant species [1, 17].
Furthermore, our study reported, for the ﬁrst time
in humans, a concurrent colonization with two diﬀerent
Arcobacter species, namely A. butzleri and A. cryaerophilus,
an occurrence that has been reported for animals [5, 38], for
water and food products [23, 35]. Thus, the coexistence of
two species in the same stool samples was found in a single
patient with cultural method, but it was shown at higher
ratesbyPCR(20patients,43.5%).Thelatterﬁndingssuggest
the possibility of multiple sources of contaminations or
the consumption of water or food products simultaneously
contamined with both species.
Epidemiological data on the occurrence of arcobacters
in humans show diﬀerent prevalence rates, both in asymp-
tomatic and symptomatic subjects [1, 14, 15], especially
those obtained by molecular methods [1, 33, 39]. Although
our detection rate is considerably higher when compared to
thesestudies,theprevalenceobtainedinourdiabeticpatients
with no gastrointestinal disease is hardly comparable with
the variable data obtained from healthy subjects, of diﬀerent
ages [1, 14, 15]. Furthermore, the generally low socio-
economical status of subjects participating to our study may
be another issue in favouring arcobacters transmission [40],
although no diﬀerences were noted in the instruction level
between carriers and non carriers of these microorganisms,
either in diabetic or in control subjects.
Several metabolic and nonmetabolic factors, such as
age, hypertension, waist circumference, and diabetes, were
all associated with arcobacters carriage in our study par-
ticipants; however, in the whole study group, only type 2
diabetes and an older age were signiﬁcant and independent
risk factors for Arcobacter colonization in this population,
with a risk that was 7- and 6-fold higher in diabetic and
older subjects as compared to nondiabetic and younger ones,
respectively.
The very high arcobacters carriage rate found in our
diabetic patients largely conﬁrms their generally high sus-
ceptibility to infections, related to the hyperglycaemic milieu
that favours bacterial growth, as well as to an altered motility
of gastroenteric tract, as a consequence of autonomic neu-
ropathyand/ormicroangiopathy,ortotheimpairedhumoral
and cellular host defence [20, 24, 25].
Notably, the very high prevalence of arcobacters detected
in type 2 diabetic and older patients, together with the
potential decline of their immune system competency [41],
may pose these subjects at higher risk of infection.
Althoughconductedinasmallsample,ourresultsclearly
indicate that older subjects and those with type 2 diabetes
are at greater risk for arcobacters carriage; large prospective
studies are needed to evaluate the potential health risk
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